Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-10

Clinical Trial Update: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) [Phase 3]

View source ↗

Summary

The Phase 3 IMPAHCT-FUL trial evaluating inhaled imatinib for pulmonary arterial hypertension was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Imatinib (inhaled formulation) (imatinib)

Snippet

Sponsor: Aerovate Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2024-10-10